博雅生物
(300294)
| 流通市值：124.30亿 | | | 总市值：124.30亿 |
| 流通股本：5.04亿 | | | 总股本：5.04亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,007,772,869.56 | 535,876,732.9 | 1,734,904,402.71 | 1,245,107,779.6 |
| 营业收入 | 1,007,772,869.56 | 535,876,732.9 | 1,734,904,402.71 | 1,245,107,779.6 |
| 二、营业总成本 | 806,442,005.67 | 409,830,144.22 | 1,279,267,786.34 | 853,438,255.57 |
| 营业成本 | 473,581,390.22 | 247,566,329.7 | 613,214,874.16 | 415,047,987.13 |
| 税金及附加 | 10,140,260.4 | 5,250,072.74 | 18,483,761.64 | 12,960,180.36 |
| 销售费用 | 195,662,191.21 | 99,836,139.1 | 419,587,310.64 | 273,785,234.14 |
| 管理费用 | 113,220,398.4 | 50,028,827.33 | 186,665,698.91 | 127,759,054.31 |
| 研发费用 | 23,180,142.42 | 10,566,848.19 | 66,889,890.67 | 47,378,915.31 |
| 财务费用 | -9,342,376.98 | -3,418,072.84 | -25,573,749.68 | -23,493,115.68 |
| 其中:利息费用 | 454,554.7 | 92,756.68 | 664,233.66 | 125,070.13 |
| 其中:利息收入 | 7,233,878.7 | 3,959,625.5 | 29,430,779.84 | 23,873,998.69 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 37,004,306.86 | 24,736,567.4 | 65,582,550.87 | 60,816,469.74 |
| 加:投资收益 | 2,529,169.37 | 1,901,515.3 | 13,061,606.76 | 7,811,944.55 |
| 资产处置收益 | 5,280,299.53 | 13,657.4 | -611,748.07 | -302,546.14 |
| 资产减值损失(新) | -286,299.07 | -220,819.03 | -83,825,238.02 | 628,571.77 |
| 信用减值损失(新) | -9,376,429.37 | -7,634,572.55 | -7,495,696.91 | -2,906,848.49 |
| 其他收益 | 26,241,973.52 | 17,593,829.74 | 34,906,649.43 | 22,587,554.44 |
| 四、营业利润 | 262,723,884.73 | 162,436,766.94 | 477,254,740.43 | 480,304,669.9 |
| 加:营业外收入 | 2,583,673.84 | 1,069,886.2 | 6,883,629.91 | 5,986,732.7 |
| 减:营业外支出 | 1,821,451.36 | 153,809.38 | 6,424,817.25 | 5,866,127.73 |
| 五、利润总额 | 263,486,107.21 | 163,352,843.76 | 477,713,553.09 | 480,425,274.87 |
| 减:所得税费用 | 38,076,492.97 | 24,061,065.28 | 81,185,061.68 | 67,992,997.01 |
| 六、净利润 | 225,409,614.24 | 139,291,778.48 | 396,528,491.41 | 412,432,277.86 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 225,409,614.24 | 139,291,778.48 | 396,528,491.41 | 412,432,277.86 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 225,340,907.9 | 139,484,155.03 | 396,991,588.69 | 412,703,629.27 |
| 少数股东损益 | 68,706.34 | -192,376.55 | -463,097.28 | -271,351.41 |
| 扣除非经常损益后的净利润 | 165,551,058.53 | 102,261,123.1 | 301,566,307.78 | 336,130,172.45 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.45 | 0.28 | 0.79 | 0.82 |
| (二)稀释每股收益 | 0.45 | 0.28 | 0.79 | 0.82 |
| 八、其他综合收益 | -3,337,574.7 | -370,420.39 | 2,363,203.42 | - |
| 归属于母公司股东的其他综合收益 | -3,337,574.7 | -370,420.39 | 2,363,203.42 | - |
| 九、综合收益总额 | 222,072,039.54 | 138,921,358.09 | 398,891,694.83 | 412,432,277.86 |
| 归属于母公司股东的综合收益总额 | 222,003,333.2 | 139,113,734.64 | 399,354,792.11 | 412,703,629.27 |
| 归属于少数股东的综合收益总额 | 68,706.34 | -192,376.55 | -463,097.28 | -271,351.41 |
| 公告日期 | 2025-08-23 | 2025-04-25 | 2025-03-19 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |